Regulations.gov document
Electronic Submission of Expedited Safety Reports From Investigational New Drug-Exempt…
Notice · FDA-2022-D-1173 · posted Apr 2, 2024
Key facts
| Document ID | FDA-2022-D-1173-0003 |
|---|---|
| Title | Electronic Submission of Expedited Safety Reports From Investigational New Drug-Exempt Bioavailability/ Bioequivalence Studies; Guidance for Industry; Availability |
| Document type | Notice |
| Subtype | Notice of Availability |
| Agency | FDA |
| Docket | FDA-2022-D-1173 |
| Posted | Apr 2, 2024 |
| Federal Register citation | 89 FR 22728 |
| FR document number | 2024-06726 |
| Comment period opens | Apr 2, 2024 |
| Effective date | Apr 2, 2024 |
At a glance
- 1–9 Pages
- None Public comments on this docket
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Regulations.gov documents
Regulations.gov holds the rulemaking and other documents federal agencies post for public comment. Only agency documents are published here; public submissions are not.
Source: Regulations.gov (U.S. General Services Administration eRulemaking Program) · Source date: